{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T05:04:43Z","timestamp":1794719083482,"version":"4.9.1"},"reference-count":155,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.semarthrit.2022.151956","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T04:46:17Z","timestamp":1641789977000},"page":"151956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"special_numbering":"C","title":["Immunopathogenesis of Beh\u00e7et's disease and treatment modalities"],"prefix":"10.1016","volume":"52","author":[{"given":"T.B.","family":"van der Houwen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"van Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.M.","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.semarthrit.2022.151956_bib0001","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","article-title":"Beh\u00e7et's disease","volume":"341","author":"Sakane","year":"1999","journal-title":"N Engl J Med"},{"issue":"8697","key":"10.1016\/j.semarthrit.2022.151956_bib0002","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et's disease. International study group for Beh\u00e7et's disease","volume":"335","year":"1990","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151956_bib0003","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The international criteria for Beh\u00e7et's disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.151956_bib0004","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/archopht.1982.01030040433013","article-title":"Close association of HLA-Bw51 with Beh\u00e7et's disease","volume":"100","author":"Ohno","year":"1982","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.semarthrit.2022.151956_bib0005","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/art.24642","article-title":"HLA-B51\/B5 and the risk of Beh\u00e7et's disease: a systematic review and meta-analysis of case-control genetic association studies","volume":"61","author":"De Menthon","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151956_bib0006","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/rheumatology\/ker428","article-title":"Relationships of HLA-B51 or B5 genotype with Behcet's disease clinical characteristics: systematic review and meta-analyses of observational studies","volume":"51","author":"Maldini","year":"2012","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.151956_bib0007","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ng.625","article-title":"Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Beh\u00e7et's disease","volume":"42","author":"Remmers","year":"2010","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.151956_bib0008","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/ng.624","article-title":"Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Beh\u00e7et's disease susceptibility loci","volume":"42","author":"Mizuki","year":"2010","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151956_bib0009","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/ng.2520","article-title":"Genome-wide association analysis identifies new susceptibility loci for Beh\u00e7et's disease and epistasis between HLA-B*51 and ERAP1","volume":"45","author":"Kirino","year":"2013","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.151956_bib0010","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1136\/annrheumdis-2015-209059","article-title":"A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Beh\u00e7et's disease in HLA-B\u221751 carriers","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.151956_bib0011","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.3389\/fimmu.2018.02463","article-title":"How ERAP1 and ERAP2 shape the peptidomes of disease-associated MHC-I proteins","volume":"9","author":"L\u00f3pez De Castro","year":"2018","journal-title":"Front Immunol"},{"issue":"23","key":"10.1016\/j.semarthrit.2022.151956_bib0012","doi-asserted-by":"crossref","first-page":"9680","DOI":"10.1074\/jbc.M117.789180","article-title":"The Beh\u00e7et's disease-associated variant of the aminopeptidase ERAP1 shapes a low-affinity HLA-B*51 peptidome by differential subpeptidome processing","volume":"292","author":"Guasp","year":"2017","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151956_bib0013","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/art.39430","article-title":"The peptidome of Beh\u00e7et's disease-associated HLA-B\u221751:01 includes two subpeptidomes differentially shaped by endoplasmic reticulum aminopeptidase 1","volume":"68","author":"Guasp","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.151956_bib0014","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2015.147","article-title":"MHC-I-opathy\u2019-unified concept for spondyloarthritis and Beh\u00e7et disease","volume":"11","author":"Mcgonagle","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.151956_bib0015","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/archopht.125.10.1375","article-title":"Human leukocyte antigen B27 and B51 double-positive Beh\u00e7et uveitis","volume":"125","author":"Jae","year":"2007","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151956_bib0016","article-title":"Association of HLA-B27 and Behcet's disease: a systematic review and meta-analysis","volume":"10","author":"Khabbazi","year":"2019","journal-title":"Autoimmun Highlights"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151956_bib0017","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.humimm.2006.11.010","article-title":"IL-10 genotype analysis in patients with Beh\u00e7et's disease","volume":"68","author":"Wallace","year":"2007","journal-title":"Hum Immunol"},{"key":"10.1016\/j.semarthrit.2022.151956_bib0018","first-page":"589","article-title":"Interleukin-10 gene polymorphisms are associated with Behcet's disease but not with vogt-koyanagi-harada syndrome in the Chinese han population","volume":"21","author":"Hu","year":"2015","journal-title":"Mol Vis"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.151956_bib0019","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.imbio.2014.03.004","article-title":"Polymorphisms of interleukin 6 and interleukin 10 in egyptian people with Behcet's disease","volume":"219","author":"Talaat","year":"2014","journal-title":"Immunobiology"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.151956_bib0020","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/ard.2009.119420","article-title":"IL-23R gene confers susceptibility to Behcet's disease in a Chinese Han population","volume":"69","author":"Jiang","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.151956_bib0021","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.humimm.2016.09.006","article-title":"Association study of rs924080 and rs11209032 polymorphisms of IL23R-IL12RB2 in a Northern Chinese Han population with Behcet's disease","volume":"77","author":"Qin","year":"2016","journal-title":"Hum Immunol"},{"key":"10.1016\/j.semarthrit.2022.151956_bib0022","first-page":"1913","article-title":"Polymorphisms in the tumor necrosis factor gene and susceptibility to Behcet's disease: an updated meta-analysis","volume":"19","author":"Zhang","year":"2013","journal-title":"Mol Vis"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151956_bib0023","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3109\/14397595.2013.844304","article-title":"Interleukin-1-related genes polymorphisms in Turkish patients with Beh\u00e7et disease: a meta-analysis","volume":"24","author":"Zou","year":"2014","journal-title":"Mod Rheumatol"},{"issue":"4 Suppl 67","key":"10.1016\/j.semarthrit.2022.151956_bib0024","first-page":"S28","article-title":"Association of interleukin-2, interleukin-4 and transforming growth factor-beta gene polymorphisms with Behcet's disease","volume":"29","author":"Shahram","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151956_bib0025","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/iji.12039","article-title":"Interleukin-2 gene polymorphism in Turkish patients with Beh\u00e7et's disease and its association with ocular involvement","volume":"40","author":"Y\u00fccel","year":"2013","journal-title":"Int J Immunogenet"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.151956_bib0026","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/j.1572-0241.2004.40304.x","article-title":"Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis","volume":"99","author":"Economou","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151956_bib0027","doi-asserted-by":"crossref","first-page":"424","DOI":"10.2174\/1566524016666160316153038","article-title":"Higher expression of NOD1 and NOD2 is associated with vogt-koyanagi-harada (VKH) syndrome but not Behcet's disease (BD)","volume":"16","author":"Deng","year":"2016","journal-title":"Curr Mol Med"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.151956_bib0028","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/rheumatology\/kep292","article-title":"Low prevalence of NOD2 SNPs in Beh\u00e7et's disease suggests protective association in Caucasians","volume":"48","author":"Kappen","year":"2009","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151956_bib0029","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s11033-012-2175-x","article-title":"Toll-like receptor polymorphisms and vasculitis susceptibility: meta-analysis and systematic review","volume":"40","author":"Song","year":"2013","journal-title":"Mol Biol Rep"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.151956_bib0030","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/jama.2020.13719","article-title":"Presence of genetic variants among young men with severe COVID-19","volume":"324","author":"Van Der Made","year":"2020","journal-title":"JAMA J Am Med Assoc"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151956_bib0031","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2013-204475","article-title":"FUT2: filling the gap between genes and environment in Beh\u00e7et's disease?","volume":"74","author":"Xavier","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2 Suppl 53","key":"10.1016\/j.semarthrit.2022.151956_bib0032","first-page":"S32","article-title":"Association of salivary S. mutans colonisation and mannose-binding lectin deficiency with gender in Beh\u00e7et's disease","volume":"27","author":"Mumcu","year":"2009","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.151956_bib0033","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/eji.1830240712","article-title":"Fine antigen specificity of human gamma delta T cell lines (V gamma 9+) established by repetitive stimulation with a serotype (KTH-1) of a gram-positive bacterium, streptococcus sanguis","volume":"24","author":"Mochizuki","year":"1994","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151956_bib0034","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/0008-8749(92)90207-6","article-title":"Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behcet's disease","volume":"140","author":"Hirohata","year":"1992","journal-title":"Cell Immunol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151956_bib0035","first-page":"506","article-title":"Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Beh\u00e7et's disease\u2013a multicenter study. The Behcet's disease research committee of Japan","volume":"16","year":"1989","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.151956_bib0036","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/art.1780391216","article-title":"The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Beh\u00e7et's disease. A randomized clinical trial","volume":"39","author":"Calg\u00fcneri","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151956_bib0037","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/rheumatology\/27.4.300","article-title":"Treatment with acyclovir does not affect orogenital ulcers in behc\u00e7et's syndrome: a randomized double-blind trial","volume":"27","author":"Davies","year":"1988","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151956_bib0038","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","article-title":"Current Concepts in the etiology and treatment of Beh\u00e7et disease","volume":"50","author":"Evereklioglu","year":"2005","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151956_bib0039","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.autrev.2014.11.009","article-title":"Beh\u00e7et's syndrome patients exhibit specific microbiome signature","volume":"14","author":"Consolandi","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151956_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153746","article-title":"Bifidobacteria abundance-featured gut microbiota compositional change in patients with Behcet's disease","volume":"11","author":"Shimizu","year":"2016","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151956_bib0041","doi-asserted-by":"crossref","first-page":"27150","DOI":"10.3402\/jom.v7.27150","article-title":"The oral mucosal and salivary microbial community of Beh\u00e7et's syndrome and recurrent aphthous stomatitis","volume":"7","author":"Seoudi","year":"2015","journal-title":"J Oral Microbiol"},{"key":"10.1016\/j.semarthrit.2022.151956_bib0042","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.3389\/fimmu.2020.01192","article-title":"Beh\u00e7et's disease under microbiotic surveillance? a combined analysis of two cohorts of Beh\u00e7et's disease patients","volume":"11","author":"Van Der Houwen","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151956_bib0043","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/08830189709116842","article-title":"The role of heat shock protein, microbial and autoimmune agents in the aetiology of Beh\u00e7et's disease","volume":"14","author":"Lehner","year":"1997","journal-title":"Int Rev Immunol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151956_bib0044","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1076\/ocii.9.2.85.3973","article-title":"Circulating antibodies to inducible heat shock protein 70 in patients with uveitis","volume":"9","author":"De Smet","year":"2001","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151956_bib0045","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1167\/iovs.09-4313","article-title":"Immune responses to interphotoreceptor retinoid-binding protein and S-antigen in Behcet's patients with uveitis","volume":"51","author":"Takeuchi","year":"2010","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151956_bib0046","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1568010053622894","article-title":"Beh\u00e7et's disease as an autoinflammatory disorder","volume":"4","author":"G\u00fcl","year":"2005","journal-title":"Curr Drug Targets Inflamm Allergy"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151956_bib0047","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00403-009-1008-9","article-title":"The skin pathergy test: innately useful?","volume":"302","author":"Varol","year":"2010","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151956_bib0048","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/rheumatology\/kes399","article-title":"Pro-inflammatory cytokine and caspase-1 responses to pattern recognition receptor activation of neutrophils and dendritic cells in Behcet's disease","volume":"52","author":"T\u00fcre-\u00d6zdemir","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2022.151956_bib0049","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaa251","article-title":"Leukocyte toll-like receptor expression in pathergy positive and negative Beh\u00e7et's disease patients","author":"Van Der Houwen","year":"2020","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.151956_bib0050","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1167\/iovs.13-12159","article-title":"Higher expression of toll-like receptors 2, 3, 4, and 8 in ocular Behcet's disease","volume":"54","author":"Liu","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151956_bib0051","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/1753425913498042","article-title":"The role of TLR2 and 4 in Beh\u00e7et's disease pathogenesis","volume":"20","author":"Seoudi","year":"2014","journal-title":"Innate Immun"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151956_bib0052","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00296-007-0470-y","article-title":"Differential expression of toll-like receptor 6 on granulocytes and monocytes implicates the role of microorganisms in Behcet's disease etiopathogenesis","volume":"28","author":"Yavuz","year":"2008","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151956_bib0053","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/rheumatology\/ken109","article-title":"Effects of vitamin D on expression of toll-like receptors of monocytes from patients with Behcet's disease","volume":"47","author":"Do","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2022.151956_bib0054","article-title":"Inflammasomes and autoimmune and rheumatic diseases: a comprehensive review","volume":"103","author":"Jae-Il","year":"2019","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151956_bib0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12950-015-0086-z","article-title":"Increased expression of the NLRP3 inflammasome components in patients with Beh\u00e7et's disease","volume":"12","author":"Kim","year":"2015","journal-title":"J Inflamm"},{"issue":"7939","key":"10.1016\/j.semarthrit.2022.151956_bib0056","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(75)80031-6","article-title":"Leucocyte movement and colchicine treatment in Behcet's disease","volume":"2","author":"Matsumura","year":"1975","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151956_bib0057","first-page":"849","article-title":"Neutrophil CD64 expression in Beh\u00e7et's disease","volume":"32","author":"Ureten","year":"2005","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.151956_bib0058","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1136\/annrheumdis-2018-214335","article-title":"Critical role of neutrophil extracellular traps (NETs) in patients with Behcet's disease","volume":"78","author":"Le Joncour","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.151956_bib0059","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3389\/fimmu.2019.01085","article-title":"Beh\u00e7et's syndrome as a model of thrombo-inflammation: the role of neutrophils","volume":"10","author":"Emmi","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151956_bib0060","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s11739-018-1991-y","article-title":"Vascular Beh\u00e7et's syndrome: an update","volume":"14","author":"Emmi","year":"2019","journal-title":"Intern Emerg Med"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.151956_bib0061","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151956_bib0062","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/cei.12939","article-title":"Circulating NK cells and their subsets in Beh\u00e7et's disease","volume":"188","author":"Hasan","year":"2017","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151956_bib0063","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1586\/eci.09.27","article-title":"Natural killer cells: versatile roles in autoimmune and infectious diseases","volume":"5","author":"Aktas","year":"2009","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151956_bib0064","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/08820139.2017.1288240","article-title":"Natural killer cell subsets and their functional activity in Beh\u00e7et's disease","volume":"46","author":"Cosan","year":"2017","journal-title":"Immunol Invest"},{"issue":"6 Suppl 94","key":"10.1016\/j.semarthrit.2022.151956_bib0065","first-page":"S24","article-title":"Natural killer cells dominate a Th-1 polarized response in Beh\u00e7et's disease patients with uveitis","volume":"33","author":"Kucuksezer","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151956_bib0066","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/ar3005","article-title":"Natural killer cells control a T-helper 1 response in patients with Beh\u00e7et's disease","volume":"12","author":"Yamaguchi","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151956_bib0067","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/sj.jid.5700527","article-title":"T helper type 2-biased natural killer cell phenotype in patients with pemphigus vulgaris","volume":"127","author":"Takahashi","year":"2007","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151956_bib0068","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1172\/JCI11819","article-title":"Natural killer type 2 bias in remission of multiple sclerosis","volume":"107","author":"Takahashi","year":"2001","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151956_bib0069","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nri3384","article-title":"Six-of-the-best: unique contributions of \u03b3\u03b4 T cells to immunology","volume":"13","author":"Vantourout","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151956_bib0070","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1189\/jlb.1105640","article-title":"Sex-specific phenotypical and functional differences in peripheral human Vgamma9\/Vdelta2 T cells","volume":"79","author":"Caccamo","year":"2006","journal-title":"J Leukoc Biol"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.151956_bib0071","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1182\/blood-2003-04-1016","article-title":"Flexible migration program regulates gamma delta T-cell involvement in humoral immunity","volume":"102","author":"Brandes","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2022.151956_bib0072","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/705831","article-title":"Gamma delta (\u03b3\u03b4) T cells and their involvement in Beh\u00e7et's disease","volume":"2015","author":"Hasan","year":"2015","journal-title":"J Immunol Res"},{"issue":"9004","key":"10.1016\/j.semarthrit.2022.151956_bib0073","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(96)90868-5","article-title":"Role of gamma delta T cells in pathogenesis and diagnosis of Behcet's disease","volume":"347","author":"Hasan","year":"1996","journal-title":"Lancet"},{"issue":"1\u20132","key":"10.1016\/j.semarthrit.2022.151956_bib0074","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0165-5728(02)00208-4","article-title":"Vgamma9Vdelta2 T cells recovered from eyes of patients with Beh\u00e7et's disease recognize non-peptide prenyl pyrophosphate antigens","volume":"130","author":"Verjans","year":"2002","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.semarthrit.2022.151956_bib0075","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.coi.2015.03.007","article-title":"Regulation of human helper T cell subset differentiation by cytokines","volume":"34","author":"Schmitt","year":"2015","journal-title":"Curr Opin Immunol"},{"issue":"7198","key":"10.1016\/j.semarthrit.2022.151956_bib0076","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/nature07036","article-title":"Induction and effector functions of T(H)17 cells","volume":"453","author":"Bettelli","year":"2008","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151956_bib0077","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/03009740600905380","article-title":"Expression of cytokines, chemokines, and chemokine receptors in oral ulcers of patients with Behcet's disease (BD) and recurrent aphthous stomatitis is Th1-associated, although Th2-association is also observed in patients with BD","volume":"35","author":"Dalghous","year":"2006","journal-title":"Scand J Rheumatol"},{"issue":"4 Suppl 60","key":"10.1016\/j.semarthrit.2022.151956_bib0078","first-page":"S27","article-title":"A Th1 but not a Th17 response is present in the gastrointestinal involvement of Beh\u00e7et's disease","volume":"28","author":"Ferrante","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151956_bib0079","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/030097402320318387","article-title":"Cytokine profile in Beh\u00e7et's disease patients. Relationship with disease activity","volume":"31","author":"Hamzaoui","year":"2002","journal-title":"Scand J Rheumatol"},{"issue":"2 Suppl 53","key":"10.1016\/j.semarthrit.2022.151956_bib0080","first-page":"S37","article-title":"Pronounced interferon-alpha production from plasmacytoid dendritic cells in patients with Beh\u00e7et's disease following CpG D ODN stimulation","volume":"27","author":"Pay","year":"2009","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151956_bib0081","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1084\/jem.185.5.825","article-title":"Selective expression of an interleukin-12 receptor component by human T helper 1 cells","volume":"185","author":"Rogge","year":"1997","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.151956_bib0082","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.autrev.2014.08.019","article-title":"Th17 cells in inflammation and autoimmunity","volume":"13","author":"Singh","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"4 Suppl 60","key":"10.1016\/j.semarthrit.2022.151956_bib0083","first-page":"S16","article-title":"Imbalance of Th17 to Th1 cells in Beh\u00e7et's disease","volume":"28","author":"Kim","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.151956_bib0084","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1167\/iovs.07-1390","article-title":"Upregulated IL-23 and IL-17 in Beh\u00e7et patients with active uveitis","volume":"49","author":"Chi","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3 Suppl 77","key":"10.1016\/j.semarthrit.2022.151956_bib0085","first-page":"32","article-title":"Up-regulation of Th17 and related cytokines in Beh\u00e7et's disease corresponding to disease activity","volume":"31","author":"Na","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.151956_bib0086","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1007\/s10067-018-4049-7","article-title":"Correlation between IL-17A\/F, IL-23, IL-35 and IL-12\/-23 (p40) levels in peripheral blood lymphocyte cultures and disease activity in Behcet's patients","volume":"37","author":"Sonmez","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.151956_bib0087","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaut.2015.08.013","article-title":"The immunogenetics of Beh\u00e7et's disease: a comprehensive review","volume":"64","author":"Takeuchi","year":"2015","journal-title":"J Autoimmun"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151956_bib0088","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/cmi.2015.10","article-title":"FOXP3+ regulatory T cells and their functional regulation","volume":"12","author":"Li","year":"2015","journal-title":"Cell Mol Immunol"},{"issue":"5 Suppl 42","key":"10.1016\/j.semarthrit.2022.151956_bib0089","first-page":"S71","article-title":"CD4+CD25+ regulatory T cells in patients with Beh\u00e7et's disease","volume":"24","author":"Hamzaoui","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.151956_bib0090","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1007\/s00296-013-2835-8","article-title":"Regulatory T cells in Beh\u00e7et's disease: is there a correlation with disease activity? Does regulatory T cell type matter?","volume":"33","author":"G\u00fcnd\u00fcz","year":"2013","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151956_bib0091","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaci.2011.05.029","article-title":"Critical role of IL-21 in modulating TH17 and regulatory T cells in Beh\u00e7et disease","volume":"128","author":"Geri","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151956_bib0092","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/art.1780290209","article-title":"Abnormal B cell function in patients with Beh\u00e7et's disease","volume":"29","author":"Suzuki","year":"1986","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151956_bib0093","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2133.1993.tb00172.x","article-title":"Anticardiolipin antibodies in adamantiades-Behcet's disease","volume":"128","author":"Zouboulis","year":"1993","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.151956_bib0094","first-page":"2404","article-title":"Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Beh\u00e7et's disease","volume":"26","author":"Mader","year":"1999","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151956_bib0095","first-page":"826","article-title":"Phenotypic characteristics of B cells in Beh\u00e7et's disease: increased activity in B cell subsets","volume":"26","author":"Ek\u015fioglu-Demiralp","year":"1999","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151956_bib0096","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","article-title":"Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study)","volume":"13","author":"Davatchi","year":"2010","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151956_bib0097","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/rheumatology\/kew366","article-title":"Chronic signs of memory B cell activation in patients with Beh\u00e7et's disease are partially restored by anti-tumour necrosis factor treatment","volume":"56","author":"Van Der Houwen","year":"2017","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151956_bib0098","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et's syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151956_bib0099","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.amjmed.2014.12.010","article-title":"Colchicine: old and new","volume":"128","author":"Slobodnick","year":"2015","journal-title":"Am J Med"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.151956_bib0100","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","article-title":"A double-blind trial of colchicine in Beh\u00e7et's syndrome","volume":"44","author":"Yurdakul","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151956_bib0101","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3109\/s10165-009-0200-2","article-title":"Colchicine versus placebo in Beh\u00e7et's disease: randomized, double-blind, controlled crossover trial","volume":"19","author":"Davatchi","year":"2009","journal-title":"Mod Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151956_bib0102","first-page":"399","article-title":"A double blind study of colchicine in Beh\u00e7et's disease","volume":"65","author":"Aktulga","year":"1980","journal-title":"Haematologica"},{"key":"10.1016\/j.semarthrit.2022.151956_bib0103","unstructured":"Corral L.G., Haslett P.A.J., Muller G.W., Chen R., Wong L.M, Ocampo C.J., Rebecca T. Patterson DIS and GK. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha PubMed [Internet]. [cited 2020 Jun 21]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10384139\/"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151956_bib0104","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":"Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome: a randomized, double-blind, placebo-controlled trial","volume":"128","author":"Hamuryudan","year":"1998","journal-title":"Ann Intern Med"},{"issue":"Vol 6 No 6","key":"10.1016\/j.semarthrit.2022.151956_bib0105","first-page":"1","article-title":"Lenalidomide: an alternative treatment for refractory Beh\u00e7et's disease and relapsing polychondritis","volume":"6","author":"Brazao","year":"2019","journal-title":"Eur J Case Rep Intern Med"},{"key":"10.1016\/j.semarthrit.2022.151956_bib0106","first-page":"1029","article-title":"Lenalidomide for treatment of recurrent oral aphthae in adamantiades-beh\u00e7et's disease","volume":"16","author":"Ossorio-Garc\u00eda","year":"2018","journal-title":"JDDG J Ger Soc Dermatol"},{"key":"10.1016\/j.semarthrit.2022.151956_bib0107","first-page":"197","article-title":"Successful treatment of Beh\u00e7et's disease with lenalidomide","volume":"158","author":"Green","year":"2008","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151956_bib0108","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1346-8138.2002.tb00263.x","article-title":"Dapsone in Beh\u00e7et's disease: a double-blind, placebo-controlled, cross-over study","volume":"29","author":"Sharquie","year":"2002","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151956_bib0109","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1177\/039463200702000318","article-title":"Pentoxifylline inhibits V\u03b39\/V\u03b42 T lymphocyte activation of patients with active Beh\u00e7et's disease in vitro","volume":"20","author":"Accardo-Palumbo","year":"2007","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.151956_bib0110","doi-asserted-by":"crossref","first-page":"891","DOI":"10.7326\/0003-4819-124-10-199605150-00005","article-title":"Successful treatment of beh\u00e7et disease with pentoxifylline","volume":"124","author":"Yasui","year":"1996","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151956_bib0111","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2209\/tdcpublication.42.169","article-title":"Combination therapy including pentoxifylline for entero-Beh\u00e7et's disease","volume":"42","author":"Hisamatsu","year":"2001","journal-title":"Bull Tokyo Dent Coll"},{"key":"10.1016\/j.semarthrit.2022.151956_bib0112","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00296-009-1305-9","article-title":"Pentoxifylline for the treatment of anterior uveitis in Behcet's disease: possible alternative for TNF blockers","volume":"31","author":"Appenzeller","year":"2011","journal-title":"Rheumatol Int Rheumatol Int"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151956_bib0113","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1741-7015-11-96","article-title":"Phosphodiesterase 4-targeted treatments for autoimmune diseases","volume":"11","author":"Kumar","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.semarthrit.2022.151956_bib0114","doi-asserted-by":"crossref","unstructured":"Hatemi G, Mahr A, Takeno M, Kim DY, Melikoglu M, Cheng S, et\u00a0al. OP0082 apremilast for Beh\u00e7et's syndrome: a phase iii randomised, placebo-controlled, double-blind study (RELIEF). In: WEDNESDAY, 13 JUNE 2018: BMJ Publishing Group Ltd and European League Against Rheumatism; 2018 p. 91\u201392.","DOI":"10.1136\/annrheumdis-2018-eular.5627"},{"issue":"16","key":"10.1016\/j.semarthrit.2022.151956_bib0115","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","article-title":"Apremilast for Beh\u00e7et's syndrome\u2013a phase 2, placebo-controlled study","volume":"372","author":"Hatemi","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151956_bib0116","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJM198202113060615","article-title":"Azathioprine decreases suppressor T cells in patients with multiple sclerosis","volume":"306","author":"Trotter","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2022.151956_bib0117","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/03009748709096717","article-title":"Modes of action of second-line agents","volume":"64","author":"Bacon","year":"1987","journal-title":"Scand J Rheumatol Suppl"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151956_bib0118","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A controlled trial of azathioprine in Beh\u00e7et's syndrome","volume":"322","author":"Yazici","year":"1990","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151956_bib0119","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1749-6632.1993.tb17137.x","article-title":"The mechanism of action of FK-506 and cyclosporin A","volume":"696","author":"Wiederrecht","year":"1993","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151956_bib0120","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0167-5699(92)90111-J","article-title":"The mechanism of action of cyclosporin A and FK506","volume":"13","author":"Schreiber","year":"1992","journal-title":"Immunol Today"},{"key":"10.1016\/j.semarthrit.2022.151956_bib0121","first-page":"880","article-title":"Production of interleukin-17 in Behcet's disease is inhibited by cyclosporin a","volume":"16","author":"Chi","year":"2010","journal-title":"Mol Vis"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151956_bib0122","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bjo.76.4.241","article-title":"Low dose cyclosporin a versus pulsed cyclophosphamide in Beh\u00e7et's syndrome: a single masked trial","volume":"76","author":"Ozyazgan","year":"1992","journal-title":"Br J Ophthalmol"},{"issue":"8647","key":"10.1016\/j.semarthrit.2022.151956_bib0123","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Beh\u00e7et's disease","volume":"1","author":"Masuda","year":"1989","journal-title":"Lancet"},{"issue":"3 Suppl 4","key":"10.1016\/j.semarthrit.2022.151956_bib0124","first-page":"136","article-title":"Evaluation of conventional therapy versus cyclosporine a in Beh\u00e7et's syndrome","volume":"20","author":"Benezra","year":"1988","journal-title":"Transpl Proc"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151956_bib0125","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1089\/jop.1994.10.553","article-title":"Low dose cyclosporin-a therapy in Beh\u00e7et's disease","volume":"10","author":"Sajjadi","year":"1994","journal-title":"J Ocul Pharmacol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151956_bib0126","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s10067-005-0070-8","article-title":"CNS involvement occurs more frequently in patients with Beh\u00e7et's disease under cyclosporin a (CSA) than under other medications results of a retrospective analysis of 117 cases","volume":"25","author":"K\u00f6tter","year":"2006","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151956_bib0127","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/bjo.2009.158840","article-title":"Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Beh\u00e7et disease","volume":"94","author":"Yamada","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151956_bib0128","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/ard.2006.064279","article-title":"Adalimumab: a new modality for Beh\u00e7et's disease?","volume":"66","author":"Van Laar","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151956_bib0129","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for Beh\u00e7et's disease: analysis of published data on 369 patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2022.151956_bib0130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et's disease: multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.semarthrit.2022.151956_bib0131","doi-asserted-by":"crossref","DOI":"10.1002\/art.41026","article-title":"Comparative study of infliximab versus adalimumab in refractory uveitis due to Beh\u00e7et's disease, national multicenter study of 177 cases","author":"Atienza-Mateo","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151956_bib0132","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.autrev.2014.12.009","article-title":"IFN-\u03b1 induces IL-10 production and tilt the balance between Th1 and Th17 in Beh\u00e7et disease","volume":"14","author":"Touzot","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151956_bib0133","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/rheumatology\/keq330","article-title":"IFN blocks IL-17 production by peripheral blood mononuclear cells in Behcet's disease","volume":"50","author":"Liu","year":"2011","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.151956_bib0134","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/0145-2126(92)90047-B","article-title":"Immunological studies of gamma delta T cells in a case of large granular lymphocyte (LGL) leukemia: leukemic gamma delta+ T cells are resistant to growth stimulation in vitro but respond to interferon-alpha treatment in vivo","volume":"16","author":"Metzger","year":"1992","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151956_bib0135","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/bio.606","article-title":"Effect of interferon-alpha on production of reactive oxygen species by human neutrophils","volume":"16","author":"Koie","year":"2001","journal-title":"Luminescence"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151956_bib0136","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","article-title":"The use of interferon alpha in Beh\u00e7et disease: review of the literature","volume":"33","author":"K\u00f6tter","year":"2004","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151956_bib0137","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s11739-019-02035-1","article-title":"Update on the treatment of Beh\u00e7et's syndrome","volume":"14","author":"Esatoglu","year":"2019","journal-title":"Intern Emerg Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151956_bib0138","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/rheumatology\/keq366","article-title":"A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Beh\u00e7et's disease: a comparative 4-week study","volume":"50","author":"Markomichelakis","year":"2011","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.151956_bib0139","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.amjmed.2004.05.027","article-title":"Pulmonary artery aneurysms in Beh\u00e7et syndrome","volume":"117","author":"Hamuryudan","year":"2004","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151956_bib0140","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.151956_bib0141","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/art.40235","article-title":"Brief report: drug-free long-term remission in severe Beh\u00e7et's disease following withdrawal of successful anti-tumor necrosis factor treatment","volume":"69","author":"Sfikakis","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.151956_bib0142","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.ophtha.2018.02.020","article-title":"Successful optimization of adalimumab therapy in refractory uveitis due to Beh\u00e7et's disease","volume":"125","author":"Mart\u00edn-Varillas","year":"2018","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151956_bib0143","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","article-title":"Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study","volume":"71","author":"G\u00fcl","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151956_bib0144","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","article-title":"Efficacy and safety profile of anti-interleukin-1 treatment in Beh\u00e7et's disease: a multicenter retrospective study","volume":"35","author":"Emmi","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.151956_bib0145","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","article-title":"Anakinra treatment in drug-resistant Behcet's disease: a case series","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151956_bib0146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2014.08.008","article-title":"Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Beh\u00e7et's disease","volume":"14","author":"Cantarini","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151956_bib0147","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/09273948.2018.1511810","article-title":"The presence of uveitis is associated with a sustained response to the interleukin (IL)-1 inhibitors anakinra and canakinumab in Beh\u00e7et's disease","volume":"28","author":"Fabiani","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151956_bib0148","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/rheumatology\/kex480","article-title":"Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Beh\u00e7et's disease: multicentre retrospective study","volume":"57","author":"Atienza-Mateo","year":"2018","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151956_bib0149","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.semarthrit.2020.05.017","article-title":"Effectiveness of tocilizumab in Behcet's disease: a systematic literature review","volume":"50","author":"Akiyama","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151956_bib0150","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.semarthrit.2022.151956_bib0151","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.151956_bib0152","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/art.40912","article-title":"Long-term outcome of ustekinumab therapy for Beh\u00e7et's disease","volume":"71","author":"Mirouse","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151956_bib0153","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.151956_bib0154","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151956_bib0155","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.jaci.2016.10.022","article-title":"Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition","volume":"139","author":"Canna","year":"2017","journal-title":"J Allergy Clin Immunol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222000075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222000075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:07:11Z","timestamp":1758733631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222000075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":155,"alternative-id":["S0049017222000075"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151956","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunopathogenesis of Beh\u00e7et's disease and treatment modalities","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151956","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151956"}}